en · de · es
analytical-notes.peptides5388.com › Guide › Background And Pharmacological Mechanism — Deep Dive

Background And Pharmacological Mechanism — Deep Dive

By Editorial Desk · published 2026-03-10 · last reviewed 2026-04-28 · Guide

The short version of freeze-thaw cycle fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2026-04-28 and is reviewed periodically as new material appears.

Background and Pharmacological Mechanism

Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.

SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.

SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.

Background and Mechanism

Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.

At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.

Sr9009 at a glance

PropertyValueNotes
Molecular formulaC20H24ClN3O4SReported for the free base
Molecular weight437.9 g/molCalculated from the formula
Primary targetREV-ERBα and REV-ERBβNuclear receptors involved in circadian regulation
SolubilitySoluble in DMSO and ethanolPoorly soluble in water
Typical storage-20 °C, desiccatedProtect from light and moisture

Identity, Handling, and Regulation

Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.

Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.

Related pages on this site

Analytical Detection and Storage

Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.

Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.

Mechanism and Preclinical Findings

SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.

Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.

The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.

Further detail

S. affinis is planted as a bulb (vegetative) in spring (March–May). Multiple bulbs are planted 5 to 8 cm (2 to 3+1⁄8 in) deep into a hole of dimensions 30 by 30 cm (12 by 12 in). The plant can achieve a height of 30 cm (12 in). Weeding is necessary but it is important not to damage the root system. A sufficient water supply during summer is important. Harvest is from November to March. It is important that the soil is not frozen when harvesting. The storage of S. affinis tubers is difficult. Because of their thin skin, they can be stored only for a few days, about a week in a fridge. An alternative can be a fresh ongoing harvesting out of humid sand, thereby the tubers stay fresh for several months.

Inadequate intake (often unmasked in refeeding after long-term low phosphate intake) Increased excretion (e.g. in hyperparathyroidism, hypophosphatemic rickets) Shift of phosphorus from the extracellular to the intracellular space. This can be seen in treatment of diabetic ketoacidosis, refeeding, short-term increases in cellular demand (e.g. hungry bone syndrome) and acute respiratory alkalosis.

==== Date disbanded ==== For legions that are documented into the 4th century and beyond, we do not know when or how they were terminated. For legions disappearing from the record before 284, the reason (certain or likely) is given as:

Studies on deep sea shrimp have shown the potential for flood lights used on the sea floor used in studying the vent systems to cause permanent retinal damage, warranting further research into the potential risk to other vent organisms. On top of the risk presented to deep-sea organisms, the surface support vessels use nocturnal anthropogenic lighting. Research has shown that this type of lighting on the ocean surface can disorient seabirds and cause fallout, where they fly toward the anthropogenic light and become exhausted or collide with man-made objects, resulting in injury or death. There is consideration for both aquatic and land organisms when evaluating the environmental effects of hydrothermal vent mining. There are three mining waste processes, known as the side cast sediment release, dewatering process, and sediment shift or disturbance, that would be expected with the deep-sea mining processes and could result in the accumulation of a sediment plume or cloud, which can have substantial environmental implications. The side cast sediment release is a process that would occur at the seafloor and would involve the move of material at the seafloor by the submerged ROV's and would most likely contribute to the formation of sediment plumes at the seafloor. The idea of side cast release is that the ROV's would discard economically invaluable material to the side of the mining sight before transporting the sulfide material to the supporting vessel at the surface.

Dermcidin is a protein with 110 amino acids that in humans is encoded by the DCD gene. The full-length protein produces derived peptides as proteolysis-inducing factor (PIF) and other anti-microbial peptides, secreted by human eccrine sweat glands onto the skin as a part of the innate host defense of the immune system. PIF is involved in muscular proteolysis.

Sources: en.wikipedia.org

Background from the literature

==== Roots ==== The word root is developed to include a vowel sound following the term to add a smoothing action to the sound of the word when applying a suffix. The result is the formation of a new term with a vowel attached (word root + vowel) called a combining form. In English, the most common vowel used in the formation of the combining form is the letter -o-, added to the word root. For example, if there is an inflammation of the stomach and intestines, this would be written as gastro- and enter- plus -itis, gastroenteritis. The formation of plurals should usually be done using the rules of the source language. Greek and Latin each have differing rules to be applied when forming the plural form of the word root.

==== Europe ==== In 2008, the European Monitoring Centre for Drugs and Drug Addiction noted that although there were some reports of tablets being sold for as little as €1, most countries in Europe then reported typical retail prices in the range of €3 to €9 per tablet, typically containing 25–65 mg of MDMA. By 2014 the EMCDDA reported that the range was more usually between €5 and €10 per tablet, typically containing 57–102 mg of MDMA, although MDMA in powder form was becoming more common.

== Keratin removal == Keratin that is present in the hair, scales and in the epidermis of the skin is hydrolyzed in the presence of alkali (at pH values greater than 11.5). The disulfide bridges found in keratin protein are cleaved but can be reformed. Long periods of liming will result in hair removal. The main removal of keratin is performed during the unhairing operation. In traditional processing, liming and unhairing were indivisible and took place at the same time. During modern liming methods, and in particular the processing of sheepskins, the hair is removed first and then limed in a liming drum. In hair-save technology, the hides are unhaired first and then limed for a further 12–18 hours.

=== On a post-apartheid society === Biko hoped that a future socialist South Africa could become a completely non-racial society, with people of all ethnic backgrounds living peacefully together in a "joint culture" that combined the best of all communities. He did not support guarantees of minority rights, believing that doing so would continue to recognise divisions along racial lines. Instead he supported a one person, one vote system. Initially arguing that one-party states were appropriate for Africa, he developed a more positive view of multi-party systems after conversations with Woods. He saw individual liberty as desirable, but regarded it as a lesser priority than access to food, employment, and social security.

Sources: en.wikipedia.org

Reference notes

Of those, Karger can isolate 4 that may be of interest as cervical cancer markers. Today, liquid chromatographers using multi-dimensional LC can isolate compounds at the femtomole (10−15 mole) and attomole (10−18 mole) levels. After a drug has been approved by the U.S. Food and Drug Administration (FDA), the emphasis at a pharmaceutical company is on getting a product to market. This is where prep or process scale chromatography has a role. In contrast to analytical analysis, preparatory scale chromatography focuses on isolation and purity of compounds. There is a trade-off between the degree of purity of compound and the amount of time required to achieve that purity. Unfortunately, many of the preparatory or process scale solutions used by pharmaceutical companies are proprietary, due to difficulties in patenting a process. Hence, there is not a great deal of literature available. However, some attempts to address the problems of prep scale chromatography include monoliths and simulated moving beds. A comparison of immunoglobulin protein capture on a conventional column and a monolithic column yields some economically interesting results. If processing times are equivalent, process volumes of IgG, an antibody, are 3,120L for conventional columns versus 5,538L for monolithic columns. This represents a 78% increase in process volume efficiency, while at the same time only a tenth of the media waste volume is generated.

Culbertson Jr.; 15,000 people are needed for each shuttle mission; the external tank has a half million gallons of fuel; the shuttle launches on the fourth attempt, two months after the first attempt; at 61,000 ft, it was at 1,700 mph; the rocket boosters were always jettisoned after two minutes and ten seconds; if two engines failed, the shuttle would land at Banjul International Airport in west Africa, if one engine failed, the shuttle would reach orbit; Hubert Brasseux, in charge of the shuttle toilet system - astronauts were strapped down to the toilet, and each had colour-coded individual urinal funnels; the Space Shuttle Orbital Maneuvering System is fired, in preparation for atmospheric entry; reentry occurs on day eleven - the underside reaches 2000C; the orbiter lands at 300 mph.

== Bioinformatics == Owing to the increasing complexity of regulation of cellular processes and the roles proteases play in them, bioinformatics continues to be an invaluable tool for degradomics. Software, databases, and projects developed for this purpose have accompanied the advancement in technology. Software developed in the Overall Lab (CLIPPER) statistically evaluates cleavage site candidates determined by degradomic approaches. One web-based data site, WebPICS, incorporates and integrates cleavage site analysis from PICS experiments into MEROPS, the protease database. Another database, Termini oriented protein Function Inferred Database (TopFIND), serves as a knowledge base to integrate protein termini formed by protease processing with functional interpretations. By combining research literature and other biological databases including UniProt, MEROPS, Ensembl, and TisDB, the database comprehensively renders protein termini modifications accessible to a broad scientific community. Using TopFIND, terminal modifications can be identified and visualized across proteins thanks to all available in silico, in vitro, and in vivo findings. Using TopFINDer and Path FINDer software, research findings can be mathematically modelled into a network of pathways regulated by proteases, further contributing to the “protease web”.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.

How does it work?

It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.

Is it proven to increase endurance in humans?

No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.

What is SR9009?

SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.

Network